Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.

× No keyword cloud information.

29 in total

Review 1. Targeting of leukemia-initiating cells in acute promyelocytic leukemia.

Authors: Ugo Testa; Francesco Lo-Coco
Journal: Stem Cell Investig Date: 2015-04-29

2. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors: Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal: Blood Date: 2019-01-23 Impact factor: 22.113

3. Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.

Authors: Lin Fu; Jinlong Shi; Jia Liu; Anqi Liu; Kailin Xu; Xiaoyan Ke
Journal: Stem Cell Investig Date: 2016-12-19

Review 4. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

Authors: Maximilian Stahl; Martin S Tallman
Journal: Leuk Lymphoma Date: 2019-12-16

Review 5. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.

Authors: Lorenzo Falchi; Srdan Verstovsek; Farhad Ravandi-Kashani; Hagop M Kantarjian
Journal: Cancer Date: 2015-12-30 Impact factor: 6.860

6. Analysis of the Characteristics of Dominant Diseases in Traditional Chinese Medicine: Based on 95 Diseases.

Authors: Hanting Wu; Yi Liang; Qiushuang Li; Peijie Hei; Juan Liang; Rongchen Dai; Conghua Ji
Journal: Evid Based Complement Alternat Med Date: 2022-06-06 Impact factor: 2.650

7. Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial.

Authors: Senlin Luo; Jidong Tian; Xiao Sun; Feifeng Wu; Ying Liu; Wuqing Wan; Zhou She; Chuan Wen
Journal: Evid Based Complement Alternat Med Date: 2022-07-05 Impact factor: 2.650

Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.